Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a novel medication for treating type 2 diabetes (T2DM), which have the pleiotropic effect of weight reduction. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.